In the News
THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ECHOES CONCERNS RAISED BY SENATORS WARNER AND MARKEY AND COLLEAGUES
CMS FAILS TO FAIRLY EVALUATE ALZHEIMER’S TREATMENTS Washington, D.C. (March 23, 2022) — Adding to the growing number of advocates calling on the U.S. Centers for Medicare and Medicaid Services (CMS) to reconsider an unprecedented National Coverage Determination (NCD) that discriminates against 6 million people with Alzheimer’s disease, U.S. Senators Mark R. Warner (D-VA) and […]
Alzheimer’s group amps public pressure with ad campaign as Medicare decision looms
A new seven-figure ad campaign takes aim – again – at Medicare’s pending coverage decision on Alzheimer’s disease anti-amyloid drugs. UsAgainstAlzheimer’s launched the $1 million-plus national effort Sunday, including a TV ad that ran across the the day’s morning talk news shows. The group is the latest to push back on the Centers for Medicare […]
Thanks to innovative research being done locally at Charter Research, volunteering for an Alzheimer’s clinical trial could improve your health and make a huge impact on the Alzheimer’s community and the future of this insidious disease
GAP-Net Site Charter Research’s Jeff Pohlig, CEO, wrote an Op-Ed about how volunteering can improve your health and your community. Unfortunately, over 90% of research studies are delayed because of slow recruitment. These delays may be affecting the treatment of your neighbor, loved one, co-worker or friend. Floridians facing Alzheimer’s need clinical trial volunteers to […]
STATEMENT BY JOHN DWYER, PRESIDENT OF THE GLOBAL ALZHEIMER’S PLATFORM FOUNDATION® ON PRESIDENT BIDEN’S STATE OF THE UNION ADDRESS
Washington, D.C. (March 1, 2022) – “He did it again. From his victory speech in November 2020 and then again in his initial address to the nation in 2021, and then tonight in his most major address yet unveiling his ‘Unity Agenda,’ President Biden put Alzheimer’s disease near the top of the U.S. national public […]
Four Alzheimer’s Clinical Trial Volunteers Honored with National Citizen Scientist Awards® for Their Work in Search of a Cure
Global Alzheimer’s Platform Foundation® Honorees Include the First Canadian Recipient, Advocate to Veterans, Caregiver, and First Honoree with Parkinson’s Disease Contact: Andi Zucchi – [email protected], 360-927-8767 Washington, DC (February 23, 2022) – The Global Alzheimer’s Platform Foundation (GAP) is honoring four clinical trial volunteers with 2021 National Citizen Scientist Awards. This year’s recipients include the […]
Medicare’s Draft Policy For Alzheimer’s Drugs And The Question Of Cost
GAP President John Dwyer was featured in Pink Sheet talking about the cost of Aduhelm affecting the Centers for Medicare and Medicaid Services NCD. US Medicare coverage policy is supposed to be fenced off from considerations about the cost of a prescription drug (or other item or service). But the notion that the cost of […]
MedVadis Research Joins GAP-Net in Fight to Accelerate Alzheimer’s Treatment
MedVadis Research will join the Global Alzheimer’s Platform Foundation® Network (GAP-Net) of more than 100 global clinical trial sites Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private […]
“Punitive, restrictive and unprecedented”: Global Alzheimer’s Platform Foundation President® John Dwyer Comments on CMS Draft National Coverage Determination
Dwyer calls on Centers for Medicare & Medicaid Services to provide coverage for the entire class of mAb drugs approved by the Food & Drug Administration and future drugs yet to be approved Washington, D.C. (February 11, 2022) – The Centers for Medicare & Medicaid Services (CMS) proposed plan to limit coverage of an entire […]
Clinicians and Researchers Urge CMS to Reform Decision to Limit Coverage of Alzheimer’s Treatments
Experts voice concerns over pre-judging promising treatments in the pipeline Today, five top Alzheimer’s clinicians and researchers called into question the preliminary proposal from the Centers for Medicare and Medicaid Services (CMS) to limit coverage FDA-approved monoclonal antibodies that target amyloid for the treatment of Alzheimer’s disease. The CMS proposal would alter the course of […]
Will Medicare Cover Aduhelm? Translating the CMS’s ‘Very Confusing’ Plan
Being Patient answers some common questions regarding the Centers for Medicare and Medicaid Services (CMS) proposal, and GAP President John Dwyer mentions how this could affect future Alzheimer’s trials and treatments. The CMS proposed a plan that could strip Alzheimer’s drug Aduhelm of public Medicare coverage. The result was widespread confusion. We clarify some aspects […]